Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A personalized mRNA cancer vaccine just delivered a landmark result. The phase 3 INTerpath-001 trial found that adding intismeran autogene to pembrolizumab cut the risk of recurrence or death by 42% and distant metastasis or death by 38% in patients with resected high-risk melanoma. Researchers are calling it a new benchmark for adjuvant melanoma treatment — and a defining moment for personalized cancer medicine.
A personalized mRNA cancer vaccine just delivered a landmark result. The phase 3 INTerpath-001 trial found that adding intismeran autogene — an individualized mRNA therapy encoding up to 34 tumor-specific neoantigens — to standard adjuvant pembrolizumab significantly improved outcomes in patients with completely resected stage IIB–IV melanoma. Results were presented at the 2026 ESMO Congress in Madrid.
The trial enrolled 1,137 patients, randomly assigning them 2:1 to receive intismeran plus pembrolizumab or placebo plus pembrolizumab. The vaccine is custom-built for each patient using next-generation sequencing of their tumor, a process that takes 6–8 weeks — which explains why benefits only became apparent after the first 6 months of follow-up.
By the Numbers:
Why it matters: This is the first phase 3 trial to validate a personalized mRNA neoantigen therapy in oncology, marking a potential paradigm shift in how cancer is treated — not by tumor type, but by each patient's unique mutational fingerprint. Full results are expected in The New England Journal of Medicine on November 11, 2026.
